Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, United States of America.
Center for Neural Basis of Cognition, Pittsburgh, PA, United States of America.
J Neural Eng. 2021 Mar 19;18(4). doi: 10.1088/1741-2552/abe8f1.
Intracortical microelectrodes are an important tool for neuroscience research and have great potential for clinical use. However, the use of microelectrode arrays to treat neurological disorders and control prosthetics is limited by biological challenges such as glial scarring, which can impair chronic recording performance. Microglia activation is an early and prominent contributor to glial scarring. After insertion of an intracortical microelectrode, nearby microglia transition into a state of activation, migrate, and encapsulate the device. Na/Hexchanger isoform-1 (NHE-1) is involved in various microglial functions, including their polarity and motility, and has been implicated in pro-inflammatory responses to tissue injury. HOE-642 (cariporide) is an inhibitor of NHE-1 and has been shown to depress microglial activation and inflammatory response in brain injury models.In this study, the effects of HOE-642 treatment on microglial interactions to intracortical microelectrodes was evaluated using two-photon microscopy.The rate at which microglia processes and soma migrate in response to electrode implantation was unaffected by HOE-642 administration. However, HOE-642 administration effectively reduced the radius of microglia activation at 72 h post-implantation from 222.2m to 177.9m. Furthermore, treatment with HOE-642 significantly reduced microglial encapsulation of implanted devices at 5 h post-insertion from 50.7 ± 6.0% to 8.9 ± 6.1%, which suggests an NHE-1-specific mechanism mediating microglia reactivity and gliosis during implantation injury.This study implicates NHE-1 as a potential target of interest in microglial reactivity and HOE-642 as a potential treatment to attenuate the glial response and scar formation around implanted intracortical microelectrodes.
皮层内微电极是神经科学研究的重要工具,具有很大的临床应用潜力。然而,微电极阵列在治疗神经疾病和控制假肢方面的应用受到生物挑战的限制,例如神经胶质瘢痕形成,这会损害慢性记录性能。小胶质细胞激活是神经胶质瘢痕形成的早期和突出贡献者。在插入皮层内微电极后,附近的小胶质细胞转变为激活状态,迁移并包裹设备。钠/氢交换蛋白异构体-1(NHE-1)参与小胶质细胞的各种功能,包括其极性和运动性,并与组织损伤的促炎反应有关。HOE-642(cariporide)是 NHE-1 的抑制剂,已被证明可抑制脑损伤模型中小胶质细胞的激活和炎症反应。在这项研究中,使用双光子显微镜评估了 HOE-642 处理对皮层内微电极中小胶质细胞相互作用的影响。HOE-642 给药并不影响微胶质细胞对电极植入的反应过程和胞体迁移速度。然而,HOE-642 给药可有效减少植入后 72 小时微胶质细胞激活的半径,从 222.2m 减小到 177.9m。此外,HOE-642 治疗可显著减少植入后 5 小时微胶质细胞对植入设备的包裹,从 50.7±6.0%减少到 8.9±6.1%,这表明 NHE-1 特异性机制介导了植入损伤期间的小胶质细胞反应性和神经胶质增生。这项研究表明 NHE-1 可能是小胶质细胞反应性的一个潜在靶点,HOE-642 可能是一种潜在的治疗方法,可减轻植入皮层内微电极周围的神经胶质反应和瘢痕形成。